$INM

InMed Pharmaceuticals (NASDAQ: INM) set November 5, 2026, as the record date for distributing contingent value rights (CVRs) to shareholders, pending approval of the merger with Mentari Therapeutics and shareholder approval of the Return of Capital Proposal at the November 4, 2026, meeting. The CVRs will be issued under a CVR Agreement, with each shareholder receiving one CVR per common share held as of the record date, but no CVRs will be issued for shares from stock options.

ADAR1 Capital Management, LLC purchased 42,920 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.33 ($1.33–$1.33) across 3 trades over 2026-10-01 to 2026-10-05. Filed jointly with Schneeberger Daniel (10% owner).

InMed Pharmaceuticals (NASDAQ: INM) received a Nasdaq notification for failing to meet the minimum shareholders' equity requirement of $2.5M, reporting $1.075M. The company attributes this to merger-related expenses and other costs. InMed expects to regain compliance post-merger with Mentari Therapeutics, anticipating $490M in gross proceeds. The company has 45 days to submit a compliance plan and may receive a 180-day extension. The merger is expected to close in Q4 2026, subject to shareholder

InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Nasdaq: INM c/o Norton Rose Fulbright Canada LLP Suite 1800-510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Stockholders’ Equi

ADAR1 Capital Management, LLC purchased 91,101 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at an average of $1.30 ($1.29–$1.30, $0.12M total) across 3 trades over 2026-09-14 to 2026-09-16. Filed jointly with Schneeberger Daniel (10% owner).

InMed Pharmaceuticals (INM) reported a net loss of $12.9M for FY2026, up from $8.2M in FY2025. The company is pursuing a merger with Mentari Therapeutics, expected to close by year-end, with Mentari raising $490M in pre-closing financing. InMed's legacy programs, including INM-901, INM-089, and INM-755, are being pursued for strategic opportunities. The company had $2.2M in cash as of June 30, 2026.

InMed Pharmaceuticals reported a net loss of $12.6M for FY 2026, with cash reserves expected to last until Q3 2026. The company ceased its revenue operations and is focusing on R&D, pending a merger or new funding.

Mentari Therapeutics raised an additional $200 million via a private placement ahead of its planned merger with InMed Pharmaceuticals (NASDAQ:INM). The deal also closes alongside a previously announced $290 million private placement. Funds extend Mentari’s cash runway into 2029 to support Phase 2a readouts for PACAP-targeted programs, including MT-002. Post-merger, the company will trade on Nasdaq under a new ticker.

InMed Pharmaceuticals (INM) rose in pre-market after merger partner Mentari Therapeutics announced a $200 million private placement of common stock and pre-funded warrants. Mentari said the funds extend its runway to 2029 and support Phase 2a readouts for PACAP programs, including MT-002. The all-stock merger with InMed is expected to close in 2H 2026.

Vivo Opportunity, LLC purchased 20,546 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at $1.55 across 6 trades over 2026-07-14 to 2026-07-16.